**Table 3 - Follow-up for inflammatory markers**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcomes** | **Crude analysis** |  | **Beta coefficient (Estimates) (95%CI)** | **P-value** $\* |
| **Single-dose** | **Multiple-dose** | **P-value**^ |
| Serum iron level follow-up**, Median (Q1, Q3)** | 9.70 (4.06, 14.14) | 6.10 (3.79, 9.10) | 0.09 | -0.00 (-0.44 ,0.44) | 0.99 |
| D-dimer level follow-up (mg/l)**, Median (Q1, Q3)** | 3.70 (1.49, 12.57) | 7.14 (2.31, 31.05) | 0.01 | 0.73 (0.25 ,1.22) | 0.003 |
| Fibrinogen level follow-up (gm/l)**, Median (Q1, Q3)** | 5.48 (3.72, 7.35) | 5.32 (3.19, 6.80) | 0.54 | -0.12 (-0.34 ,0.09) | 0.27 |
| CRP level follow-up (mg/l)**, Median (Q1, Q3)** | 188.50 (81.0, 304.0) | 175 (143.80, 105.00) | 0.93 | -0.21 (-0.60 ,0.18) | 0.30 |
| Procalcitonin level follow-up (ng/ml), )**, Median (Q1, Q3)** | 0.42 (0.16, 3.19) | 0.96 (0.11, 5.99) | 0.58 | 0.32 (-0.67 ,1.30) | 0.53 |
| ^ Wilcoxon rank sum test is used to calculate the P-value.$\* Multivariate logistic regression is used after adjusting for patient’s age, SOFA score, PaO2/FiO2 ratio baseline and systemic corticosteroids during ICU stay to calculate estimates and p-value. |